18F-FTC-146 PET/CT in Newly-Diagnosed Osteosarcoma

Summary

The purpose of this research is to evaluate the study drug, 18F FTC-146, as a positron emission tomography (PET) / computed tomography (CT) radiotracer imaging agent to evaluate tumor status in patients newly diagnosed with osteosarcoma ("bone cancer").

Timeline

Start

2021-01-28

Primary completion

2021-05-28

Completion

2021-07-22

Outcome

Outcome not reported

Stopped (Enrollment): “lack of accrual with no intent of continuing”

Drugs

Indications